CoChat

Diagnosis and Treatment of Mitochondrial Myopathies

Open access
Ahmed, Syeda T., Craven, Lyndsey, Russell, Oliver M., Turnbull, Doug M., Vincent, Amy E. · 2018 · Neurotherapeutics
Cited by 152

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Mitochondrial myopathies are progressive muscle conditions caused primarily by the impairment of oxidative phosphorylation (OXPHOS) in the mitochondria. This causes a deficit in energy production in the form of adenosine triphosphate (ATP), particularly in skeletal muscle. The diagnosis of mitochondrial myopathy is reliant on the combination of numerous techniques including traditional histochemical, immunohistochemical, and biochemical testing combined with the fast-emerging molecular genetic techniques, namely next-generation sequencing (NGS). This has allowed for the diagnosis to become more effective in terms of determining causative or novel genes. However, there are currently no effective or disease-modifying treatments available for the vast majority of patients with mitochondrial myopathies. Existing therapeutic options focus on the symptomatic management of disease manifestations. An increasing number of clinical trials have investigated the therapeutic effects of various vitamins, cofactors, and small molecules, though these trials have failed to show definitive outcome measures for clinical practice thus far. In addition, new molecular strategies, specifically mtZFNs and mtTALENs, that cause beneficial heteroplasmic shifts in cell lines harboring varying pathogenic mtDNA mutations offer hope for the future. Moreover, recent developments in the reproductive options for patients with mitochondrial myopathies mean that for some families, the possibility of preventing transmission of the mutation to the next generation is now possible.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13311-018-00674-4

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 62

  1. Gorman, 2016, Mitochondrial diseases, Nat Rev Dis Primers, 2, 10.1038/nrdp.2016.80 · DOI · Paper page
  2. Shoffner, 1989, Spontaneous Kearns-Sayre/chronic external ophthalmoplegia plus syndrome associated with a mitochondrial DNA deletion: a slip-replication model and metabolic therapy, Proc Natl Acad Sci U S A, 86, 7952, 10.1073/pnas.86.20.7952 · DOI · Paper page
  3. Rossignol, 2003, Mitochondrial threshold effects, Biochem J, 370, 751, 10.1042/bj20021594 · DOI · Paper page
  4. Sommerville, 2014, Adult-onset Mendelian PEO Associated with Mitochondrial Disease, J Neuromuscul Dis, 1, 119, 10.3233/JND-140041 · DOI
  5. Gorman, 2015, Perceived fatigue is highly prevalent and debilitating in patients with mitochondrial disease, Neuromuscul Disord, 25, 563, 10.1016/j.nmd.2015.03.001 · DOI · Paper page
  6. Alston, 2017, The genetics and pathology of mitochondrial disease, J Pathol, 241, 236, 10.1002/path.4809 · DOI · Paper page
  7. Moraes, 1992, The mitochondrial tRNA(Leu(UUR)) mutation in mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS): genetic, biochemical, and morphological correlations in skeletal muscle, Am J Hum Genet, 50, 934
  8. Campbell, 2014, Dissecting the mechanisms underlying the accumulation of mitochondrial DNA deletions in human skeletal muscle, Hum Mol Genet, 23, 4612, 10.1093/hmg/ddu176 · DOI
  9. Ahmed, 2017, Using a quantitative quadruple immunofluorescent assay to diagnose isolated mitochondrial Complex I deficiency, Sci Rep, 7, 10.1038/s41598-017-14623-2 · DOI
  10. Rocha, 2015, A novel immunofluorescent assay to investigate oxidative phosphorylation deficiency in mitochondrial myopathy: understanding mechanisms and improving diagnosis, Sci Rep, 5, 10.1038/srep15037 · DOI · Paper page
  11. Bernier, 2002, Diagnostic criteria for respiratory chain disorders in adults and children, Neurology, 59, 1406, 10.1212/01.WNL.0000033795.17156.00 · DOI · Paper page
  12. Taylor, 2014, Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies, JAMA, 312, 68, 10.1001/jama.2014.7184 · DOI · Paper page
  13. Frazier, 2017, Mitochondrial energy generation disorders: genes, mechanisms and clues to pathology, J Biol Chem
  14. Grady JP, Pickett SJ. mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease. 10(6) (2018). · DOI · Paper page
  15. Calvo, 2012, Molecular Diagnosis of Infantile Mitochondrial Disease with Targeted Next-Generation Sequencing, Sci Transl Med, 4, 118ra110, 10.1126/scitranslmed.3003310 · DOI · Paper page
  16. Calvo, 2006, Systematic identification of human mitochondrial disease genes through integrative genomics, Nat Genet, 38, 576, 10.1038/ng1776 · DOI · Paper page
  17. McFarland, 2010, A neurological perspective on mitochondrial disease, Lancet Neurol, 9, 829, 10.1016/S1474-4422(10)70116-2 · DOI · Paper page
  18. Grady, 2014, Disease progression in patients with single, large-scale mitochondrial DNA deletions, Brain, 137, 323, 10.1093/brain/awt321 · DOI
  19. Volpi, 2011, Metabolic myopathies: functional evaluation by different exercise testing approaches, Musculoskelet Surg, 95, 59, 10.1007/s12306-011-0096-9 · DOI
  20. Tarnopolsky, 2004, Clinical variability in maternally inherited leber hereditary optic neuropathy with the G14459A mutation, Am J Med Genet A, 124a, 372, 10.1002/ajmg.a.20449 · DOI
  21. Lehtonen, 2016, FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders, Neurology, 87, 2290, 10.1212/WNL.0000000000003374 · DOI · Paper page
  22. Morovat, 2017, Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice, J Clin Med, 6, 80, 10.3390/jcm6080080 · DOI
  23. Fujita, 2015, GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases, Mitochondrion, 20, 34, 10.1016/j.mito.2014.10.006 · DOI · Paper page
  24. Taivassalo, 2002, Venous oxygen levels during aerobic forearm exercise: An index of impaired oxidative metabolism in mitochondrial myopathy, Ann Neurol, 51, 38, 10.1002/ana.10027 · DOI · Paper page
  25. Horvath, 2012, Adult-onset cerebellar ataxia due to mutations in CABC1/ADCK3, J Neurol Neurosurg Psychiatry, 83, 174, 10.1136/jnnp-2011-301258 · DOI
  26. Glover Elisa, 2010, A randomized trial of coenzyme Q10 in mitochondrial disorders, Muscle Nerve, 42, 739, 10.1002/mus.21758 · DOI · Paper page
  27. Stacpoole, 2012, Design and Implementation of the First Randomized Controlled Trial of Coenzyme Q(10) in Children with Primary Mitochondrial Diseases, Mitochondrion, 12, 623, 10.1016/j.mito.2012.09.005 · DOI
  28. Giorgio, 2012, The effects of idebenone on mitochondrial bioenergetics, Biochim Biophys Acta, 1817, 363, 10.1016/j.bbabio.2011.10.012 · DOI · Paper page
  29. Yatsuga, 2012, Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice, Hum Mol Genet, 21, 526, 10.1093/hmg/ddr482 · DOI · Paper page
  30. Viscomi, 2011, In vivo correction of COX deficiency by activation of the AMPK/PGC-1alpha axis, Cell Metab, 14, 80, 10.1016/j.cmet.2011.04.011 · DOI · Paper page
  31. Reisman, 2014, Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis, Radiat Res, 181, 512, 10.1667/RR13578.1 · DOI · Paper page
  32. Shen, 2008, R-alpha-lipoic acid and acetyl-L-carnitine complementarily promote mitochondrial biogenesis in murine 3T3-L1 adipocytes, Diabetologia, 51, 165, 10.1007/s00125-007-0852-4 · DOI
  33. Ahola-Erkkila, 2010, Ketogenic diet slows down mitochondrial myopathy progression in mice, Hum Mol Genet, 19, 1974, 10.1093/hmg/ddq076 · DOI · Paper page
  34. Santra, 2004, Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells, Ann Neurol, 56, 662, 10.1002/ana.20240 · DOI
  35. Ahola, 2016, Modified Atkins diet induces subacute selective ragged-red-fiber lysis in mitochondrial myopathy patients, EMBO Mol Med, 8, 1234, 10.15252/emmm.201606592 · DOI · Paper page
  36. Alam, 2015, A mitochondrial therapeutic reverses visual decline in mouse models of diabetes, Dis Model Mech, 8, 701
  37. Szeto, 2014, Serendipity and the Discovery of Novel Compounds That Restore Mitochondrial Plasticity, Clin Pharmacol Ther, 96, 672, 10.1038/clpt.2014.174 · DOI · Paper page
  38. Siegel, 2013, Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice, Aging Cell, 12, 763, 10.1111/acel.12102 · DOI · Paper page
  39. Karaa, 2018, Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy, Neurology, 90, e1212, 10.1212/WNL.0000000000005255 · DOI · Paper page
  40. Koene, 2017, KH176 under development for rare mitochondrial disease: a first in man randomized controlled clinical trial in healthy male volunteers, Orphanet J Rare Dis, 12, 163, 10.1186/s13023-017-0715-0 · DOI
  41. Taivassalo, 2001, Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects, Ann Neurol, 50, 133, 10.1002/ana.1050 · DOI · Paper page
  42. Cejudo, 2005, Exercise training in mitochondrial myopathy: a randomized controlled trial, Muscle Nerve, 32, 342, 10.1002/mus.20368 · DOI · Paper page
  43. Murphy, 2008, Resistance training in patients with single, large-scale deletions of mitochondrial DNA, Brain, 131, 2832, 10.1093/brain/awn252 · DOI · Paper page
  44. Bates, 2013, Defining cardiac adaptations and safety of endurance training in patients with m.3243A>G-related mitochondrial disease, Int J Cardiol, 168, 3599, 10.1016/j.ijcard.2013.05.062 · DOI
  45. Zeviani, 2008, Train, train, train! No pain, just gain, Brain, 131, 2809, 10.1093/brain/awn264 · DOI
  46. Minczuk, 2008, Development of a single-chain, quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA, Nucleic Acids Res, 36, 3926, 10.1093/nar/gkn313 · DOI · Paper page
  47. Bacman, 2014, The Use of Mitochondria-Targeted Endonucleases to Manipulate mtDNA, Methods Enzymol, 547, 373, 10.1016/B978-0-12-801415-8.00018-7 · DOI
  48. Gammage, 2014, Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations, EMBO Mol Med, 6, 458, 10.1002/emmm.201303672 · DOI · Paper page
  49. Hashimoto, 2015, MitoTALEN: A General Approach to Reduce Mutant mtDNA Loads and Restore Oxidative Phosphorylation Function in Mitochondrial Diseases, Mol Ther, 23, 1592, 10.1038/mt.2015.126 · DOI · Paper page
  50. Gammage, 2016, Near-complete elimination of mutant mtDNA by iterative or dynamic dose-controlled treatment with mtZFNs, Nucleic Acids Res, 44, 7804, 10.1093/nar/gkw676 · DOI
  51. Reddy, 2015, Selective elimination of mitochondrial mutations in the germline by genome editing, Cell, 161, 459, 10.1016/j.cell.2015.03.051 · DOI · Paper page
  52. Garone, 2014, Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency, EMBO Mol Med, 6, 1016, 10.15252/emmm.201404092 · DOI
  53. Nesbitt, 2014, A national perspective on prenatal testing for mitochondrial disease, Eur J Hum Genet, 22, 10.1038/ejhg.2014.35 · DOI
  54. Smeets, 2015, Preventing the transmission of mitochondrial DNA disorders using prenatal or preimplantation genetic diagnosis, Ann N Y Acad Sci, 1350, 29, 10.1111/nyas.12866 · DOI
  55. Craven, 2010, Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease, Nature, 465, 82, 10.1038/nature08958 · DOI · Paper page
  56. Lyndsey, 2017, Recent Advances in Mitochondrial Disease, Annu Rev Genomics Hum Genet, 18, 257, 10.1146/annurev-genom-091416-035426 · DOI · Paper page
  57. Yamada, 2016, Genetic Drift Can Compromise Mitochondrial Replacement by Nuclear Transfer in Human Oocytes, Cell Stem Cell, 18, 749, 10.1016/j.stem.2016.04.001 · DOI · Paper page
  58. Kang, 2016, Mitochondrial replacement in human oocytes carrying pathogenic mitochondrial DNA mutations, Nature, 540, 270, 10.1038/nature20592 · DOI · Paper page
  59. Hyslop, 2016, Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease, Nature, 534, 383, 10.1038/nature18303 · DOI · Paper page
  60. Greenfield, 2017, Assisted reproductive technologies to prevent human mitochondrial disease transmission, Nat Biotechnol, 35, 10.1038/nbt.3997 · DOI
  61. Craven, 2016, Research into Policy: A Brief History of Mitochondrial Donation, Stem Cells, 34, 265, 10.1002/stem.2221 · DOI
  62. Gorman, 2015, Mitochondrial donation–how many women could benefit?, N Engl J Med, 372, 885, 10.1056/NEJMc1500960 · DOI

Cited by

See all 152

Metadata

Authors
Ahmed, S. T., Craven, L., Russell, O. M., Turnbull, D. M., & Vincent, A. E.
Venue
Neurotherapeutics
Publisher
Elsevier BV
Published
2018-10
Volume
15
Issue
4
Pages
943-953
ISSN
1878-7479 (ISSN-L)
OpenAlex
W2900029109
Cited by
152
References
14
FWCI
3.22
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • Wellcome Trust (203105/Z/16/Z)
  • Medical Research Council (MR/L016354/1)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnosis and Treatment of Mitochondrial Myopathies. https://app.cochat.ai/papers/10.1007/s13311-018-00674-4
The paper
Ahmed, S. T., Craven, L., Russell, O. M., Turnbull, D. M., & Vincent, A. E. (2018). Diagnosis and Treatment of Mitochondrial Myopathies. Neurotherapeutics. https://doi.org/10.1007/s13311-018-00674-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.